Peritoneal, aging during PD: Implication of RAGE, the receptor for AGEs

Nefrologia

Volumn 28, Issue SUPPL. 6, 2008, Pages 5-10

  Boulanger, Eric ^a,b   Daroux, M ^a  

^a Medical School   (France)

^b UNIV LILLE   (France)

Author keywords

Advanced Glycation End products (Ages); Aging; Biocompatibility; Peritoneal dialysis; RAGE

Indexed keywords

EID: 55949110617     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Davies SJ, Phillips L, Griffiths AM, Russell LH, Naish PF, Russell GL. What really happens to people on long-term peritoneal dialysis? Kidney Int 1998; 54: 2207-2217.
2. Topley N. Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions. Adv Ren Replace Ther 1998; 5: 179-184.
3. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jorres A. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11: 729-739.
4. Miyata T, Horie K, Ueda Y, Fujita Y, Izuhara Y, Hirano H, Uchida K, Saito A, Van Ypersele de Strihou C, Kurokawa K. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000; 58: 425-435.
5. Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A. 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 2002; 62: 697-703.
6. Linden T, Forsback G, Deppisch R, Henle T, Wieslander A. 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 1998; 18: 290-293.
7. Boulanger E, Wautier MP, Wautier JL, Boval B, Panis Y, Wernert N, Danze P, Dequiedt P. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002; 61: 148-156.
8. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-15004.
9. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-955.
10. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, Naka Y. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111: 959-972.
11. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108: 261-268.
12. Douvdevani A, Rapoport J, Konforty A, Argov S, Ovnat A, Chaimovitz C. Human peritoneal mesothelial cells synthesize IL-1 alpha and beta. Kidney Int 1994; 46: 993-1001.
13. Topley N, Jorres A, Luttmann W, Petersen MM, Lang MJ, Thierauch KH, Muller C, Coles GA, Davies M, Williams JD. Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1 beta and TNF alpha. Kidney Int 1993; 43: 226-233.
14. Offner FA, Feichtinger H, Stadlmann S, Obrist P, Marth C, Klingler P, Grage B, Schmahl M, Knabbe C. Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. Am J Pathol 1996; 148: 1679-1688.
15. Cannistra SA, Ottensmeier C, Tidy J, DeFranzo B. Vascular cell adhesion molecule-1 expressed by peritoneal mesothelium partly mediates the binding of activated human T lymphocytes. Exp Hematol 1994; 22: 996-1002.
16. Topley N, Kaur D, Petersen MM, Jorres A, Williams JD, Faict D, Holmes CJ. In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. J Am Soc Nephrol 1996; 7: 218-224.
17. Rougier JP, Moullier P, Piedagnel R, Ronco PM. Hyperosmolality suppresses but TGF beta 1 increases MMP9 in human peritoneal mesothelial cells. Kidney Int 1997; 51: 337-347.
18. Rougier JP, Guia S, Hagege J, Nguyen G, Ronco PM. PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-beta 1. Kidney Int 1998; 54: 87-98.
19. Rogachev B, Hausmann MJ, Yulzari R, Weiler M, Holmes C, Faict D, Chaimovitz C, Douvdevani A. Effect of bicarbonate-based dialysis solutions on intracellular pH (pHi) and TNFalpha production by peritoneal macrophages. Perit Dial Int 1997; 17: 546-553.
20. Li FK, Davenport A, Robson RL, Loetscher P, Rothlein R, Williams JD, Topley N. Leukocyte migration across human peritoneal mesothelial cells is dependent on directed chemokine secretion and ICAM-1 expression. Kidney Int 1998; 54: 2170-2183.
21. Liang Y, Sasaki K. Expression of adhesion molecules relevant to leukocyte migration on the microvilli of liver peritoneal mesothelial cells. Anat Rec 2000; 258: 39-46.
22. Boulanger E, Wautier MP, Gane P, Mariette C, Devuyst O, Wautier JL. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol Dial Transplant 2004; 19: 2208-2216.
23. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995; 146: 3-15.
24. Grossin N, Wautier MP, Wautier JL, Gane P, Taamma R, Boulanger E. Improved in vitro biocompatibility of bicarbonate-buffered peritoneal dialysis fluid. Perit Dial Int 2006; 26: 664-670.
25. De Vriese AS, Flyvbjerg A, Mortier S, Tilton RG, Lameire NH. Inhibition of the Interaction of AGE-RAGE Prevents Hyperglycemia-Induced Fibrosis of the Peritoneal Membrane. J Am Soc Nephrol 2003; 14: 2109-2118.
26. Boulanger E, Grossin N, Wautier MP, Taamma R, Wautier JL. Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int 2007; 71: 126-133.
27. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, Ritz E, Bierhaus A, Nawroth P, Zeier M. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17: 199-207.
28. Boulanger E, Moranne O, Wautier MP, Witko-Sarsat V, Descamps-Latscha B, Kandoussi A, Grossin N, Wautier JL. Changes in glycation and oxidation markers in patients starting peritoneal dialysis: a pilot study. Perit Dial Int 2006; 26: 207-212.
29. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995; 1: 447-456.